MedTech Terms
    The authoritative reference
    All terms
    Investment & FinanceStartup Lifecycle

    Pro-Rata Rights

    Right of an existing investor to maintain ownership percentage in future rounds.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    Pro-rata rights allow an investor to participate in future financings up to the amount needed to maintain their existing ownership percentage. Often called 'preemptive rights' in legal documents.
    What the regulation says
    While not directly addressed by major MedTech regulations like the FDA 21 CFR 820 (Quality System Regulation) or the EU MDR (Medical Device Regulation), pro-rata rights can indirectly impact a company's financial stability and ability to fund ongoing compliance efforts, such as post-market surveillance or quality system improvements. Regulatory bodies expect companies to maintain adequate resources to meet their obligations throughout the product lifecycle.

    What this means in practice

    Coveted in oversubscribed MedTech rounds, where insiders compete with new investors for allocation. Major funds insist on pro-rata; smaller checks may not get them.

    Examples

    • A MedTech startup raises a Series A round, and its seed investors exercise their pro-rata rights to invest more, ensuring they retain their 15% ownership. This influx of capital helps fund ongoing clinical trials and quality system upgrades.
    • During a Series B round, a major venture capital firm insists on pro-rata rights to protect its substantial investment in a promising medical device company, securing its ability to participate in future growth. This ensures continued funding for regulatory submissions and market expansion.
    • A small angel investor in a digital health company chooses not to exercise their pro-rata rights in a subsequent, larger funding round due to limited capital, leading to a reduction in their overall ownership percentage. The company still successfully raises capital for product development.
    Common pitfalls
    • •Misunderstanding pro-rata rights can lead to significant dilution for early investors if they are unable to participate in subsequent funding rounds.
    • •Failing to clearly define pro-rata rights in investment agreements can result in legal disputes and delays in securing future financing.
    • •Overlooking the operational impact of pro-rata participation can strain a company's administrative resources during fundraising.
    • •Assuming all investors will exercise their pro-rata rights can lead to miscalculations in fundraising targets and available equity.
    • •Not considering the long-term implications of granting broad pro-rata rights on future investor interest can be a mistake.

    Frequently asked questions

    No, pro-rata rights are not legally mandated but are a common provision negotiated between investors and companies, especially in competitive funding environments.
    Grouped by theme

    Primary references

    3 sources
    Link health: 3 verified· last checked 2026-06-20
    Cooley GO·1NVCA·1SVB·1
    1. 1
      Cooley GO: pro-rata
      Verified
      Cooley GOcooleygo.com
    2. 2
      NVCA Model Documents
      Verified
      NVCAnvca.org
    3. 3
      Silicon Valley Bank - Healthcare Reports
      Verified
      SVBsvb.com

    Inline markers like [1] jump to the matching reference above.